Escitalopram in the treatment of generalized anxiety disorder
Escitalopram in the treatment of generalized anxiety disorder
The selective serotonin reuptake inhibitor escitalopram is the active enantiomer of citalopram and has proven efficacy in the treatment of major depression, panic disorder and social phobia. Accumulating data indicate that it is also efficacious in the treatment of patients with generalized anxiety disorder. This drug profile summarizes the current evidence-base for the treatment of generalized anxiety disorder, describes the findings of a series of randomized placebo-controlled and comparator-controlled trials of escitalopram, examines the strengths and weaknesses of current treatment approaches and considers potential new therapies for the treatment of this common, chronic and impairing anxiety disorder. In summary, escitalopram is effective and well tolerated in both the short- and long-term treatment of generalized anxiety disorder, and has advantages over benzodiazepines and the selective serotonin reuptake inhibitor paroxetine.
efficacy, escitalopram, generalized anxiety disorder, pharmacotherapy, placebo, safety
443-449
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Nair, Rajesh V.
23d1b46a-396c-4149-93d5-f4165549b19d
2005
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Nair, Rajesh V.
23d1b46a-396c-4149-93d5-f4165549b19d
Baldwin, David S. and Nair, Rajesh V.
(2005)
Escitalopram in the treatment of generalized anxiety disorder.
Expert Review of Neurotherapeutics, 5 (4), .
(doi:10.1586/14737175.5.4.443).
Abstract
The selective serotonin reuptake inhibitor escitalopram is the active enantiomer of citalopram and has proven efficacy in the treatment of major depression, panic disorder and social phobia. Accumulating data indicate that it is also efficacious in the treatment of patients with generalized anxiety disorder. This drug profile summarizes the current evidence-base for the treatment of generalized anxiety disorder, describes the findings of a series of randomized placebo-controlled and comparator-controlled trials of escitalopram, examines the strengths and weaknesses of current treatment approaches and considers potential new therapies for the treatment of this common, chronic and impairing anxiety disorder. In summary, escitalopram is effective and well tolerated in both the short- and long-term treatment of generalized anxiety disorder, and has advantages over benzodiazepines and the selective serotonin reuptake inhibitor paroxetine.
This record has no associated files available for download.
More information
Published date: 2005
Keywords:
efficacy, escitalopram, generalized anxiety disorder, pharmacotherapy, placebo, safety
Identifiers
Local EPrints ID: 27527
URI: http://eprints.soton.ac.uk/id/eprint/27527
ISSN: 1473-7175
PURE UUID: fd418906-a48d-495d-98cb-8095cd84a0ec
Catalogue record
Date deposited: 25 Apr 2006
Last modified: 16 Mar 2024 02:48
Export record
Altmetrics
Contributors
Author:
Rajesh V. Nair
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
